Trial NCT04392713
Publication Shah Bukhari K H, medRxiv (2021) (preprint)
Primary outcome on the report: The primary end-point of the study was viral clearance and was measured as the days to achieve RT-PCR negativity following ivermectin administration.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.